Table 1.

Clinicopathological data of patients in the training and validation cohorts.

Variable	Training cohort			Validation cohort			P
	Uncommon EGFR (+)	Uncommon EGFR (-)	P	Uncommon EGFR (+)	Uncommon EGFR (-)	P
Age (mean ± SD)	64.93 ± 10.07	63.29 ± 9.89	0.273	65.47 ± 9.14	64.82 ± 13.7	0.856	0.543
Sex, n (%)			0.270			0.098	0.064
Male	45 (52.3)	41 (44.1)		16 (76.2)	12 (52.2)
Female	41 (47.7)	52 (55.9)		5 (23.8)	11 (47.8)
Smoking status, n (%)			0.879			0.063	0.822
Smoker	7 (8.1)	7 (7.5)		18 (85.7)	23 (100)
Never smoker	79 (91.9)	86 (92.5)		3 (14.3)	0 (0)
Grade, n (%)			0.036			0.032	0.137
Low/intermediate	62 (72.1)	79 (84.9)		11 (52.4)	19 (82.6)
High	24 (27.9)	14 (15.1)		10 (47.6)	4 (17.4)
Tumor marker (mean ± SD)
CEA	7.63 ± 6.13	5.78 ± 5.49	0.035	8.53 ± 8.18	4.53 ± 4.20	0.045	0.823
NSE	2.87 ± 2.27	3.03 ± 2.99	0.695	2.46 ± 1.38	3.75 ± 3.11	0.087	0.686
CA125	9.49 ± 8.39	9.63 ± 6.18	0.898	8.67 ± 11.51	6.47 ± 13.48	0.567	0.157
SCC	0.69 ± 1.29	0.81 ± 1.23	0.506	0.92 ± 1.7	0.53 ± 0.28	0.294	0.848
CY21-1	3.61 ± 9.03	3.40 ± 3.65	0.834	3.52 ± 2.59	2.06 ± 2.34	0.056	0.475
Stage, n (%)			0.060			0.216	0.266
I	52 (60.5)	58 (62.4)		11 (52.4)	15 (65.2)
II	9 (10.5)	11 (11.8)		1 (4.8)	1 (4.3)
III	10 (11.6)	2 (2.2)		0 (0)	2 (8.7)
IV	15 (17.4)	22 (23.7)		9 (42.9)	5 (21.7)
ECOG PS, n (%)			0.368			0.594	0.580
0	29 (33.7)	34 (36.6)		6 (28.6)	6 (26.1)
1	31 (36.0)	33 (35.5)		9 (42.9)	8 (34.8)
2	18 (20.9)	23 (24.7)		5 (23.8)	5 (21.7)
3	8 (9.3)	3 (3.2)		1 (4.8)	4 (17.4)
Rad_score (mean ± SD)	0.55 ± 0.68	-0.29 ± 0.68	0.001	0.40 ± 0.84	-0.48 ± 0.68	0.001	0.970

Bold values: P < 0.05.